This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Template:SubstanceBox/Buprenorphine: Difference between revisions
Jump to navigation
Jump to search
>Isaak No edit summary |
>Graham m wiki ref formatting |
||
| Line 53: | Line 53: | ||
|InsufflatedROA_Collapsed= | |InsufflatedROA_Collapsed= | ||
|InsufflatedROA_Caption= | |InsufflatedROA_Caption= | ||
|InsufflatedROA_Bioavailability=48%<ref>The systemic availability of buprenorphine administered by nasal spray. | |InsufflatedROA_Bioavailability=48%<ref name="Eriksen1989">{{cite journal | vauthors=((Eriksen, J.)), ((Jensen, N. H.)), ((Kamp-Jensen, M.)), ((Bjarnø, H.)), ((Friis, P.)), ((Brewster, D.)) | journal=The Journal of Pharmacy and Pharmacology | title=The systemic availability of buprenorphine administered by nasal spray | volume=41 | issue=11 | pages=803–805 | date= November 1989 | issn=0022-3573 | doi=10.1111/j.2042-7158.1989.tb06374.x}}</ref> | ||
|InsufflatedROA_Threshold=< 0.2 mg | |InsufflatedROA_Threshold=< 0.2 mg | ||
|InsufflatedROA_Light=0.2 - 0.4 mg | |InsufflatedROA_Light=0.2 - 0.4 mg | ||
| Line 70: | Line 70: | ||
|SublingualROA_Collapsed=true | |SublingualROA_Collapsed=true | ||
|SublingualROA_Caption= | |SublingualROA_Caption= | ||
|SublingualROA_Bioavailability= 30%<ref> | |SublingualROA_Bioavailability= 30%<ref name="Mendelson1997">{{cite journal | vauthors=((Mendelson, J.)), ((Upton, R. A.)), ((Everhart, E. T.)), ((Jacob, P.)), ((Jones, R. T.)) | journal=Journal of Clinical Pharmacology | title=Bioavailability of sublingual buprenorphine | volume=37 | issue=1 | pages=31–37 | date= January 1997 | issn=0091-2700 | doi=10.1177/009127009703700106}}</ref> | ||
|SublingualROA_Threshold=<0.3 mg | |SublingualROA_Threshold=<0.3 mg | ||
|SublingualROA_Light=0.3 - 0.6 mg | |SublingualROA_Light=0.3 - 0.6 mg | ||
Revision as of 22:17, 27 July 2022
| SubstanceBox/Buprenorphine | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common names | Buprenex, Subutex, Butrans, Cizdol, Addnok, Transtec | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Systematic name | (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Psychoactive class | Opioid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical class | Morphinan | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- ↑ Mendelson, J., Upton, R. A., Everhart, E. T., Jacob, P., Jones, R. T. (January 1997). "Bioavailability of sublingual buprenorphine". Journal of Clinical Pharmacology. 37 (1): 31–37. doi:10.1177/009127009703700106. ISSN 0091-2700.
- ↑ Eriksen, J., Jensen, N. H., Kamp-Jensen, M., Bjarnø, H., Friis, P., Brewster, D. (November 1989). "The systemic availability of buprenorphine administered by nasal spray". The Journal of Pharmacy and Pharmacology. 41 (11): 803–805. doi:10.1111/j.2042-7158.1989.tb06374.x. ISSN 0022-3573.